Development of Propionibacterium acnes-associated Sarcoidosis During Etanercept Therapy

Intern Med. 2019 May 15;58(10):1473-1477. doi: 10.2169/internalmedicine.2086-18. Epub 2019 Jan 10.

Abstract

Although numerous recent studies have reported the development of sarcoidosis in patients treated with tumor necrosis factor alpha (TNF-α) inhibitors, it is unclear whether the pathogenesis of drug-induced sarcoidosis is identical to that of spontaneous sarcoidosis. We herein present the case of a patient who developed sarcoidosis 6 months after the introduction of etanercept as treatment for rheumatoid arthritis. Typical clinical symptoms with noncaseating epithelioid granulomas detected in a mediastinal lymph node specimen were consistent with the diagnosis of sarcoidosis. Immunohistochemistry revealed Propionibacterium acnes in the noncaseating granulomas. The present findings suggest that Propionibacterium acnes is a cause of sarcoidosis, even when the disease is induced by TNF-α inhibitors.

Keywords: Propionibacterium acnes; TNF-α; etanercept; sarcoidosis.

Publication types

  • Case Reports

MeSH terms

  • Anti-Asthmatic Agents / adverse effects*
  • Anti-Asthmatic Agents / therapeutic use
  • Arthritis, Rheumatoid / complications*
  • Arthritis, Rheumatoid / drug therapy*
  • Etanercept / adverse effects*
  • Etanercept / therapeutic use*
  • Female
  • Granuloma / pathology
  • Humans
  • Lymph Nodes / pathology
  • Male
  • Mediastinum / pathology
  • Middle Aged
  • Propionibacterium acnes / pathogenicity*
  • Sarcoidosis / chemically induced*
  • Tumor Necrosis Factor-alpha / adverse effects*

Substances

  • Anti-Asthmatic Agents
  • Tumor Necrosis Factor-alpha
  • Etanercept